CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
2.2 Market beyond: what to expect by 2025
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top impacting factors
3.2.2 Top investment pockets
3.2.3 Top winning strategies
3.3 Porters five force analysis
3.3.1 Fewer suppliers lead to higher bargaining power of suppliers
3.3.2 Higher buyer concentration leads to low bargaining power
3.3.3 Low threat of substitutes due to lack of superior alternatives
3.3.4 Low threat of new entrants due to high capital investment
3.3.5 Moderate competitive rivalry
3.4 Value chain analysis
3.4.1 Research and product development
3.4.2 Product testing
3.4.3 Manufacturing
3.4.4 End users
3.5 Regulatory norms
3.6 Concerns related to synthetic biology
3.7 Market Dynamics
3.7.1 Drivers
3.7.1.1 Funding from government and Private organizations
3.7.1.2 Rising number of research facilities
3.7.1.3 Rising count of new entrants
3.7.1.4 Declining cost of DNA Sequencing
3.7.2 Restraints
3.7.2.1 Bio-safety and Bio-security Issues
3.7.2.2 Ethical concerns and stringent regulations
3.7.3 Opportunities
3.7.3.1 growing demand of bio-fuels and Bioplastics
3.7.3.2 increasing research activities in Asia Pacific region
3.7.3.3 rising R&D investments
CHAPTER 4 OVERVIEW OF NUCLEOTIDE SYNTHESIS
4.1 Technological trends in nucleotide synthesis
4.2 Commercial application scope for large DNA constructs in Europe and North America
4.2.1 Antibody engineering
4.2.2 Metabolic engineering
4.2.3 Pathway engineering
4.2.4 Other potential application
4.3 Top players positioning, 2014, (Focus on nucleotide synthesis)
4.4 Market dynamics specific to nucleotide synthesis
4.4.1 Drivers
4.4.1.1 Technical advancements in integrated sequencing
4.4.1.2 Growing demand for large DNA constructs
4.4.1.3 Increasing accountability of government funding
4.4.2 Restraints
4.4.2.1 High cost and longer duration of nucleotide synthesis
4.4.2.2 Absence of regulatory guidelines
4.4.3 Opportunities
4.4.3.1 Exploring opportunities in European countries
CHAPTER 5 WORLD SYNTHETIC BIOLOGY MARKET, BY PRODUCT
5.1 Overview
5.1.1 Market size and forecast
5.2 Synthetic DNA
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.3 Synthetic Oligonucleotides
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast
5.4 Synthetic Genes
5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
5.5 Software tools
5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast
5.6 Chassis Organisms
5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size and forecast
5.7 Synthetic Clones
5.7.1 Key market trends
5.7.2 Key growth factors and opportunities
5.7.3 Market size and forecast
5.8 Synthetic cells
5.8.1 Key market trends
5.8.2 Key growth factors and opportunities
5.8.3 Market size and forecast
CHAPTER 6 WORLD SYNTHETIC BIOLOGY MARKET, BY TECHNOLOGY
6.1 Overview
6.1.1 Market size and forecast
6.2 Nucleotide synthesis and sequencing
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.3 Bioinformatics technologies
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
6.4 Microfluidics technologies
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.5 Genetic engineering
6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
CHAPTER 7 WORLD SYNTHETIC BIOLOGY MARKET, BY APPLICATION
7.1 Overview
7.1.1 Market size and forecast
7.2 Pharmaceuticals & diagnostics
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.3 Biofuels
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.4 Chemicals
7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
7.5 Bioplastics
7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast
7.6 Others (agriculture, bioremediation and aquaculture)
7.6.1 Market size and forecast
CHAPTER 8 WORLD SYNTHETIC BIOLOGY MARKET, BY GEOGRAPHY
8.1 Overview
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key market trends
8.2.2 Key growth factors and opportunities
8.2.3 Market size and forecast
8.3 Europe
8.3.1 Key market trends
8.3.2 Key growth factors and opportunities
8.3.3 Market size and forecast
8.4 Asia Pacific
8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size and forecast
8.5 LAMEA
8.5.1 Key market trends
8.5.2 Key growth factors and opportunities
8.5.3 Market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1 GEN9 Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Strategic moves and developments
9.1.4 SWOT analysis of Gen9 Inc.
9.2 Codexis Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Business performance
9.2.4 Strategic moves and developments
9.2.5 SWOT analysis of Codexis
9.3 OriGene Technologies, Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Strategic moves and developments
9.3.4 SWOT analysis of OriGene
9.4 Synthetic Genomics, Inc.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Strategic moves and developments
9.4.4 SWOT analysis of Synthetic Genomics
9.5 Thermo fisher Scientific
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Business performance
9.5.4 Strategic moves and developments
9.5.5 SWOT analysis of Thermo fisher Scientific
9.6 GENEWIZ, Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Strategic moves and development
9.6.4 SWOT analysis of GENEWIZ, Inc.
9.7 Eurofins Scientific, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Services portfolio
9.7.4 Strategic moves and developments
9.7.5 Business performance
9.7.6 SWOT analysis of Eurofins Scientific, Inc.
9.8 Integrated DNA Technologies, Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Services Portfolio
9.8.4 Strategic moves and development
9.8.5 SWOT analysis of Integrated DNA Technologies, Inc.
9.9 DNA2.0, Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Services portfolio
9.9.4 Strategic moves and development
9.9.5 SWOT analysis of DNA2.0, Inc.
9.10 Pareto Biotechnologies
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Services Portfolio
9.10.4 Strategic moves and development
9.10.5 SWOT analysis of Pareto Biotechnologies
9.11 Synthorx, Inc.
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Services portfolio
9.11.4 SWOT analysis of Synthorx, Inc.
9.12 TeselaGen Biotechnology
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Services portfolio
9.12.4 Strategic moves and developments
9.12.5 SWOT Analysis of TeselaGen Biotechnology.
9.13 Editas Medicine, Inc.
9.13.1 Company overview
9.13.2 Company snapshot
9.13.3 Services portfolio
9.13.4 Strategic moves and development
9.13.5 SWOT analysis of Editas Medicine, Inc.
9.14 GenScript Corporation
9.14.1 Company overview
9.14.2 Company snapshot
9.14.3 Strategic moves and developments
9.14.4 SWOT analysis of GenScript
9.15 Twist Bioscience
9.15.1 Company overview
9.15.2 Company snapshot
9.15.3 Services portfolio
9.15.4 Strategic moves and developments
9.15.5 SWOT analysis of Twist Bioscience
9.16 GeneWorks Pty Ltd.
9.16.1 Company overview
9.16.2 Company snapshot
9.16.3 Services portfolio
9.16.4 SWOT analysis of GeneWorks Pty. Ltd.
9.17 Proterro, Inc.
9.17.1 Company overview
9.17.2 Company snapshot
9.17.3 Services portfolio
9.17.4 Strategic moves and developments
9.17.5 SWOT analysis of Proterro, Inc.
9.18 Blue heron (OriGene technologies Inc.)
9.18.1 Company overview
9.18.2 Company snapshot
9.18.3 Service portfolio of Blue heron (OriGene technologies Inc.)
9.18.4 SWOT analysis of Blue heron (OriGene technologies Inc.)
